Entacapone (cas 116314-67-1) and prostate cancer in Parkinson's disease patients: A large Veterans Affairs healthcare system study
-
Add time:08/02/2019 Source:sciencedirect.com
BackgroundAn increased incidence of prostate cancer was observed in Parkinson's disease (PD) patients treated with Entacapone (cas 116314-67-1) during a pre-approval randomized clinical trial; the relation has not been robustly investigated in the U.S. ambulatory setting.
We also recommend Trading Suppliers and Manufacturers of Entacapone (cas 116314-67-1). Pls Click Website Link as below: cas 116314-67-1 suppliers
Prev:Pain Behavior and Response Properties of Spinal Dorsal Horn Neurons Following Experimental Diabetic Neuropathy in the Rat: Modulation by Nitecapone (cas 116313-94-1), a COMT Inhibitor with Antioxidant Properties
Next:Micellar HPLC-UV method for the simultaneous determination of levodopa, carbidopa and Entacapone (cas 116314-67-1) in pharmaceuticals and human plasma) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- The catechol-O-methyltransferase inhibitors tolcapone and Entacapone (cas 116314-67-1) uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells08/06/2019
- A novel electrochemical nanosensor based on NH2-functionalized multi walled carbon nanotubes for the determination of catechol-orto-methyltransferase inhibitor Entacapone (cas 116314-67-1)08/05/2019
- Use of an Entacapone (cas 116314-67-1)-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database08/04/2019
- Micellar HPLC-UV method for the simultaneous determination of levodopa, carbidopa and Entacapone (cas 116314-67-1) in pharmaceuticals and human plasma08/03/2019
